# AT Impf

> AT Impf is a VC fund in Munich backing Medical, Therapeutics and Biotechnology. See 3 investments, check sizes, portfolio. Updated Aug 2026.

- Type: VC Fund
- Location: Munich, Germany
- Total investments: 3
- Last investment: Mar 2020
- Lead investor: 0%
- Last updated: Aug 2026

AT Impf is a VC fund in Munich focused on Medical and Therapeutics. AT Impf was added in 2010.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Medical | 2 | 67% |
| Therapeutics | 2 | 67% |
| Biotechnology | 2 | 67% |

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series C | 1 | 33% |
| Funding Round | 1 | 33% |
| Post-IPO Equity | 1 | 33% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| immatics biotechnologies | immatics is a biopharmaceutical company focused on the development of immunotherapeutic substances for cancer therapy. immatics has a good track record of success: They are optimistic that they have found a way to develop drugs against cancer that might one day help many cancer patients. The product candidates are designed to have less severeside effects than currently available treatment options. immatics has developed peptide-based active immunotherapy with unprecedented speed and efficiency, setting new standards for discovery and development in this area of oncology drug development. Our technology can also lead towards the development of novel immunotherapies based on antibodies and T-cell receptors. immatics is currently working on the development of new substances for a number of specific cancer types. Their most advanced product is currently being developed in a phase 3 clinical trial for kidney cancer. Final results for this trial are expected in 2015. A second product targeting colorectal cancer has just completed a large phase 1/2 clinical trial and a third cancer vaccine has entered several phase 1 clinical trials in brain cancer. They also have active earlier programs in several other tumor types including gastric cancer, non-small-cell lung cancer and prostate cancer which are being developed in collaboration with our partner Roche. | $104M | Post-IPO Equity | Mar 17, 2020 |  |
| Isarna Therapeutics | Isarna Therapeutics has an unmatched commitment to developing selective TGF-β inhibitors to effectively treat ophthalmic diseases. They are advancing a unique pipeline of novel oligonucleotides and combination modalities to transcend clinical response and improve patient outcomes. | $17.8M |  | Jan 07, 2014 |  |
| immatics biotechnologies | immatics is a biopharmaceutical company focused on the development of immunotherapeutic substances for cancer therapy. immatics has a good track record of success: They are optimistic that they have found a way to develop drugs against cancer that might one day help many cancer patients. The product candidates are designed to have less severeside effects than currently available treatment options. immatics has developed peptide-based active immunotherapy with unprecedented speed and efficiency, setting new standards for discovery and development in this area of oncology drug development. Our technology can also lead towards the development of novel immunotherapies based on antibodies and T-cell receptors. immatics is currently working on the development of new substances for a number of specific cancer types. Their most advanced product is currently being developed in a phase 3 clinical trial for kidney cancer. Final results for this trial are expected in 2015. A second product targeting colorectal cancer has just completed a large phase 1/2 clinical trial and a third cancer vaccine has entered several phase 1 clinical trials in brain cancer. They also have active earlier programs in several other tumor types including gastric cancer, non-small-cell lung cancer and prostate cancer which are being developed in collaboration with our partner Roche. | $59.2M | Series C | Sep 21, 2010 |  |

3 of 3 investments shown.

## Co-investors
- [dievini Hopp Biotech Holding](https://shizune.co/investors/profile/dievini-hopp-biotech-holding) — VC Fund, 3 deals together
- [MIG Capital](https://shizune.co/investors/profile/mig-ag) — VC Fund, 2 deals together
- [Wellington Partners](https://shizune.co/investors/profile/wellington-partners) — VC Fund, 2 deals together
- [Perceptive Advisors](https://shizune.co/investors/profile/perceptive-advisors) — VC Fund, 1 deal together
- [Redmile Group](https://shizune.co/investors/profile/redmile-group) — VC Fund, 1 deal together
- [RTW Investments](https://shizune.co/investors/profile/rtw-investments-llc) — VC Fund, 1 deal together

## Similar investors

### Similar stage
- [Sequoia Capital](https://shizune.co/investors/profile/sequoia-capital) — VC Fund
- [New Enterprise Associates](https://shizune.co/investors/profile/new-enterprise-associates) — VC Fund
- [Bessemer Venture Partners](https://shizune.co/investors/profile/bessemer-venture-partners) — VC Fund

## FAQ

### What does AT Impf invest in?

AT Impf invests primarily in Medical, Therapeutics and Biotechnology startups, most often at Series C and Funding Round stage. Most of the 3 investments tracked by Shizune back companies in Germany. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did AT Impf last invest?

The most recent investment recorded for AT Impf closed in Mar 2020. Shizune tracks 3 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co